Targeting autophagy: polydatin's role in inducing cell death in AML

Area of Science:

• Hematology
• Cancer Biology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) is a prevalent adult blood cancer originating from leukemic stem cells (LSCs).
• Polydatin (PD) exhibits potential anti-cancer properties, including enhanced tumor apoptosis and autophagy modulation.

Purpose of the Study:

• To evaluate the therapeutic potential of polydatin (PD) in acute myeloid leukemia (AML).
• To investigate PD's mechanism of action involving autophagy regulation in AML cells.

Main Methods:

• Ex vivo and in vivo studies using the KASUMI-1 AML cell line and a mouse transplant tumor model.
• Molecular docking to predict PD interaction with Autophagy-related protein 5 (ATG5).
• Assessment of cell proliferation, apoptosis, and autophagy pathway modulation.

Main Results:

• PD suppressed KASUMI-1 cell proliferation and induced apoptosis by regulating autophagy.
• Molecular docking indicated PD inhibits ATG5 ubiquitination and enhances its stability, activating autophagy.
• In vivo studies confirmed PD's effectiveness and safety in an AML mouse model.

Conclusions:

• Polydatin demonstrates significant therapeutic potential for acute myeloid leukemia (AML).
• PD's mechanism involves modulating the ATG5-mediated autophagy pathway.
• PD is a promising candidate for early AML intervention with potential clinical applications.